MLL leukemia induction by t(9;11) chromosomal translocation in human hematopoietic stem cells using genome editing by Corina Schneidawind, Johan Jeong,

Slides:



Advertisements
Similar presentations
A B C Plating rounds CD45 + Dox SOX7::GFP - Dox p2 p5 + Dox p5
Advertisements

by Ayten Kandilci, and Gerard C. Grosveld
Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID.
Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples by Keiki Kumano, Shunya Arai, Masataka Hosoi, Kazuki.
The ETS factor TEL2 is a hematopoietic oncoprotein
Constitutively Active β-Catenin Confers Multilineage Differentiation Potential on Lymphoid and Myeloid Progenitors  Yoshihiro Baba, Karla P. Garrett,
by Benjamin J. Frisch, John M. Ashton, Lianping Xing, Michael W
The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted.
Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia by Fumio Nakahara, Mamiko Sakata-Yanagimoto,
by Alexis S. Bailey, Shuguang Jiang, Michael Afentoulis, Christina I
In vivo retroviral gene transfer by direct intrafemoral injection results in correction of the SCID phenotype in Jak3 knock-out animals by Christine S.
Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib by Kathryn.
Ectopic expression of HOXC6 blocks myeloid differentiation and predisposes to malignant transformation  Melanie Wurm, John Kowalski, Dirk Heckl, Xiao-Bing.
Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.
Bone morphogenetic protein 4 induces efficient hematopoietic differentiation of rhesus monkey embryonic stem cells in vitro by Fei Li, Shijiang Lu, Loyda.
by Chi Wai So, and Michael L. Cleary
by Xiaowu Zhang, and Ruibao Ren
Francesca Ficara, Mark J. Murphy, Min Lin, Michael L. Cleary 
by Hyung-Gyoon Kim, Kyoko Kojima, C. Scott Swindle, Claudiu V
Lack of the adhesion molecules P-selectin and intercellular adhesion molecule-1 accelerate the development of BCR/ABL-induced chronic myeloid leukemia-like.
by Hiroyuki Kawagoe, and Gerard C. Grosveld
Elucidation of the EP defect in Diamond-Blackfan anemia by characterization and prospective isolation of human EPs by Deena Iskander, Bethan Psaila, Gareth.
Identification and characterization of 2 types of erythroid progenitors that express GATA-1 at distinct levels by Norio Suzuki, Naruyoshi Suwabe, Osamu.
Distinct classes of c-Kit–activating mutations differ in their ability to promote RUNX1-ETO–associated acute myeloid leukemia by Heidi J. Nick, Hyung-Gyoon.
FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant.
Volume 17, Issue 2, Pages (February 2010)
by Hairui Su, Chiao-Wang Sun, Szu-Mam Liu, Xin He, Hao Hu, Kevin M
Volume 28, Issue 2, Pages (August 2015)
Megakaryocyte-derived excessive transforming growth factor β1 inhibits proliferation of normal hematopoietic stem cells in acute myeloid leukemia  Yuemin.
Volume 30, Issue 5, Pages (November 2016)
Epigenetic Roles of MLL Oncoproteins Are Dependent on NF-κB
Volume 4, Issue 2, Pages (February 2003)
The Competitive Nature of HOXB4-Transduced HSC Is Limited by PBX1
Volume 37, Issue 5, Pages (November 2012)
Volume 25, Issue 4, Pages (April 2014)
Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells by Xiaoli Wang, Cing Siang Hu, Bruce Petersen, Jiajing.
Mouse acute leukemia develops independent of self-renewal and differentiation potentials in hematopoietic stem and progenitor cells by Fang Dong, Haitao.
C/EBPα overrides epigenetic reprogramming by oncogenic transcription factors in acute myeloid leukemia by Justin Loke, Paulynn Suyin Chin, Peter Keane,
Volume 22, Issue 2, Pages (January 2018)
Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines by Yanyan Zhang, Liang He, Dorothée.
Volume 16, Issue 5, Pages (May 2002)
Volume 23, Issue 4, Pages (April 2018)
Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells by Mia Eriksson, Pablo Peña-Martínez,
Ravindra Majeti, Christopher Y. Park, Irving L. Weissman 
MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs by Silvia Maifrede, Esteban Martinez, Margaret Nieborowska-Skorska, Daniela.
Myeloma cell–derived Runx2 promotes myeloma progression in bone
David Traver, Koichi Akashi, Irving L. Weissman, Eric Lagasse  Immunity 
Tim C.P. Somervaille, Michael L. Cleary  Cancer Cell 
Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells by Xi Jin, Tingting Qin, Meiling Zhao, Nathanael.
Hhex induces promyelocyte self-renewal and cooperates with growth factor independence to cause myeloid leukemia in mice by Jacob T. Jackson, Ashley P.
Twist1 regulates embryonic hematopoietic differentiation through binding to Myb and Gata2 promoter regions by Kasem Kulkeaw, Tomoko Inoue, Tadafumi Iino,
C/EBPβ is a critical mediator of IFN-α–induced exhaustion of chronic myeloid leukemia stem cells by Asumi Yokota, Hideyo Hirai, Ryuichi Sato, Hiroko Adachi,
Kiran Batta, Magdalena Florkowska, Valerie Kouskoff, Georges Lacaud 
Volume 3, Issue 6, Pages (December 2014)
Human hematopoietic stem cell maintenance and myeloid cell development in next-generation humanized mouse models by Trisha R. Sippel, Stefan Radtke, Tayla.
Volume 3, Issue 2, Pages (February 2003)
by Yue Wei, Hong Zheng, Naran Bao, Shan Jiang, Carlos E
Volume 17, Issue 5, Pages (October 2016)
Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia by Ross Kinstrie, Dimitris Karamitros, Nicolas Goardon, Heather Morrison,
HOXB6 overexpression results in delayed AML
Akihiko Yokoyama, Michael L. Cleary  Cancer Cell 
Proliferation of Aml1-excised immortalized BM cells is enhanced in vitro. Proliferation of Aml1-excised immortalized BM cells is enhanced in vitro. (A)
Volume 17, Issue 4, Pages (October 2015)
Volume 16, Issue 2, Pages (February 2002)
Decellularized Wharton jelly matrix: a biomimetic scaffold for ex vivo hematopoietic stem cell culture by Dandan Li, Grace Chiu, Brea Lipe, Richard A.
IL-33, IL-25, and TSLP induce a distinct phenotypic and activation profile in human type 2 innate lymphoid cells by Ana Camelo, Guglielmo Rosignoli, Yoichiro.
An Mll-Dependent Hox Program Drives Hematopoietic Progenitor Expansion
Granulocyte colony-stimulating factor mobilizes dormant hematopoietic stem cells without proliferation in mice by Jeffrey M. Bernitz, Michael G. Daniel,
Constitutive expression of JAK3M511I and HOXA9 leads to development of both AML and T-ALL in vivo. Constitutive expression of JAK3M511I and HOXA9 leads.
Volume 7, Issue 4, Pages (May 2014)
Presentation transcript:

MLL leukemia induction by t(9;11) chromosomal translocation in human hematopoietic stem cells using genome editing by Corina Schneidawind, Johan Jeong, Dominik Schneidawind, In-Suk Kim, Jesús Duque-Afonso, Stephen Hon Kit Wong, Masayuki Iwasaki, Erin H. Breese, James L. Zehnder, Matthew Porteus, and Michael L. Cleary BloodAdv Volume 2(8):832-845 April 24, 2018 © 2018 by The American Society of Hematology

Corina Schneidawind et al. Blood Adv 2018;2:832-845 © 2018 by The American Society of Hematology

Molecular and cytogenetic features of MLL-AF9–rearranged cells induced by genome editing. Molecular and cytogenetic features of MLL-AF9–rearranged cells induced by genome editing. (A) Representative PCR to detect MLL-AF9 (left) and AF9-MLL (right) translocation breakpoints in gene-edited cells at day 27 of culture (samples 1 and 2). (B) Data shown are a composite alignment of PCR products from multiple experiments (days 7-14 of culture) showing a variety of distinct translocations. Arrowheads indicate the sequence of long-term–survived clones. (C) FISH analysis using an MLL break-apart probe was performed on genome-edited cells maintained in culture for over 50 days. A representative image is shown. Arrows indicate the split signals of the break-apart probe indicating MLL translocation. (D) Representative metaphase chromosomes from karyotype analysis of genome-edited cells shows a balanced t(9;11) chromosomal translocation. Corina Schneidawind et al. Blood Adv 2018;2:832-845 © 2018 by The American Society of Hematology

Transcriptional features of genome-edited MLL-AF9 translocated cells. Transcriptional features of genome-edited MLL-AF9 translocated cells. (A) RT-PCR was performed on complementary DNA of genome-edited MLLr cells from 2 independent cultures to detect fusion transcripts. Closed arrowheads indicate MLL-AF9 and AF9-MLL fusion transcripts. Open arrowheads indicate the alternatively processed fusion transcripts, which lack MLL exon 11 and MLL exon 12 from MLL-AF9 and AF9-MLL, respectively. (B) Representative western blot analysis of MLL proteins in controls (nucleofected with GFP alone) and MLL-AF9–rearranged cells cultured either in liquid or semisolid medium. Retroviral and knock-in indicate transformed human cord blood cells by retroviral MLL-AF9 or MLL-AF9 knock-in. CFC, colony-formed cells; GAPDH, loading control; LC, liquid culture. Numbers below indicate relative MLL-AF9 band intensities compared with WT MLLN. (C) Representative qPCR analyses show expression levels of MLL target genes compared with control (nucleofected with GFP) at day 65 of culture and human leukemia cell lines. *P < .02. Error bars indicate standard deviation of triplicate analyses. MM6, Mono Mac 6; S1, sample 1; S2, sample 2; WT, wild-type. Corina Schneidawind et al. Blood Adv 2018;2:832-845 © 2018 by The American Society of Hematology

MLL-AF9 translocated cells display specific cytokine dependence profiles. MLL-AF9 translocated cells display specific cytokine dependence profiles. (A) MLL-AF9–rearranged cells cultured in the presence of SR-1 and UM729 plus the indicated single cytokines were quantified by trypan blue dye exclusion after 3 days and compared with control (all cytokines, blue bar). (B) Cells cultured with IL-3 or SCF were additionally cultured for 7 and 17 days in the presence of SR-1, UM729, the respective cytokines IL-3 or SCF, and the indicated single cytokine to evaluate their sensitivity compared with the control (all cytokines, blue bar). Error bars indicate SEM for 2 analyses. (C) Flow cytometry profiles show representative phenotypes of cells cultured in the indicated cytokine milieus after 27 days (blue lines) vs cells culture in the complete cytokine cocktail (red shading). TPO, thrombopoietin. Corina Schneidawind et al. Blood Adv 2018;2:832-845 © 2018 by The American Society of Hematology

Genome-edited primary CD34+ cells display survival advantage and clonal expansion in vitro. Genome-edited primary CD34+cells display survival advantage and clonal expansion in vitro. (A) Representative growth curves chart the differences in proliferative capacity of genome-edited CD34+ cells compared with controls (GFP or MLL TALENs alone). Arrows indicate time point of FISH analyses and karyotyping. (B) Graph shows cell viability in liquid culture monitored over time by flow cytometry and further confirmed by trypan blue dye exclusion. (C) PCR was performed for MLL-AF9 and reciprocal AF9-MLL breakpoints on genomic DNA over progressive time of culture. (D) Representative morphologies are shown for control and translocated cells on day 76 by May-Grünwald-Giemsa staining. Arrowheads indicate differentiating cells. Scale bar, 20 μm. (E) Colony-forming assays were performed on day 60 of liquid culture. Bars represent the mean number of colony-forming units (CFUs) per 104 seeded cells. (F) Plot indicates cell numbers after each replating. Experiments were performed in triplicate, and data from 2 independent experiments are shown. (G) Images show representative morphologies of colonies after each replating (R). Scale bar, 200 μm. Corina Schneidawind et al. Blood Adv 2018;2:832-845 © 2018 by The American Society of Hematology

MLL-AF9 translocated cells preferentially express CD9. MLL-AF9 translocated cells preferentially express CD9. (A) Representative flow cytometry analyses are shown for cell-surface protein expression of genome-edited MLLr cells compared with control cells (CD34+ cells nucleofected with GFP alone) at day 65. (B) Representative flow cytometry plots of CD9 expression over time in culture for genome-edited MLLr cells. (C) Representative flow cytometry plots before and after FACS sorting of genome-edited MLLr cells based on CD9 expression at day 37 of in vitro culture followed by FISH analysis for MLL translocation. (D) Representative flow cytometry plots of CD9 expression on MLLr leukemic patient samples. Red shading indicates control (fluorescence minus one); blue line denotes expression of indicated marker. SSC, side scatter. Corina Schneidawind et al. Blood Adv 2018;2:832-845 © 2018 by The American Society of Hematology

Genome-edited cells with t(9;11) chromosomal translocations induce AML Genome-edited cells with t(9;11) chromosomal translocations induce AML. (A) Experimental scheme for induction of AML by genome-edited cells following transplantation in sublethally irradiated NSG recipient mice after 98 days of in vitro culture. Genome-edited cells with t(9;11) chromosomal translocations induce AML. (A) Experimental scheme for induction of AML by genome-edited cells following transplantation in sublethally irradiated NSG recipient mice after 98 days of in vitro culture. (B) Disease-free survival of transplanted mice; *P < .009 (control vs sample 1, 1st), **P < .07 (control vs sample 2, 1st), ***P < .0001 (control vs sample 1, 2nd), and ****P < .0001 (control vs sample 2, 2nd) by log-rank test. (C-D) May-Grünwald-Giemsa staining shows blast cells in peripheral blood (PB) smear (C) and monomorphic bone marrow (BM) cells (D). Scale bar, 20 μm. (E) Increased spleen size (top) and weight (bottom) of leukemic mice compared with control; *P < .01. (F) Hematoxylin and eosin–stained sections of bone marrow, spleen, and liver. Scale bar, 100 μm. Corina Schneidawind et al. Blood Adv 2018;2:832-845 © 2018 by The American Society of Hematology

AML signature gene expression changes in the MLL-AF9 AMLs AML signature gene expression changes in the MLL-AF9 AMLs. (A) Heatmap displays gene expression profiles of MLL-AF9 rearranged cultured cells and their derived leukemic bone marrow cells. AML signature gene expression changes in the MLL-AF9 AMLs. (A) Heatmap displays gene expression profiles of MLL-AF9 rearranged cultured cells and their derived leukemic bone marrow cells. Unbiased hierarchical cluster analysis is shown for 7 primary (AML) and 2 secondary (2nd AML) leukemias compared with 2 cultured cell lines used for injection (S1, sample 1; S2, sample 2). (B) Gene set enrichment analysis plots show that genes upregulated in human LSCs were enriched in the AMLs (left, normalized enrichment score = −1.84, false discovery rate q value = 0) whereas genes downregulated in LSCs were enriched in the injected cells (right, normalized enrichment score = 1.33, false discovery rate q value <0.074). Corina Schneidawind et al. Blood Adv 2018;2:832-845 © 2018 by The American Society of Hematology